Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going

Lymphangioleiomyomatosis (LAM), a multisystem disease affecting predominantly premenopausal and middle-aged women, causes progressive respiratory failure due to cystic lung destruction and is associated with lymphatic and kidney tumors. In the past, the treatment of LAM comprised exclusively anti-es...

Descripción completa

Detalles Bibliográficos
Autores principales: Taveira-DaSilva, Angelo M, Steagall, Wendy K, Moss, Joel
Formato: Texto
Lenguaje:English
Publicado: Medicine Reports 2009
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948329/
https://www.ncbi.nlm.nih.gov/pubmed/20948684
http://dx.doi.org/10.3410/M1-93
_version_ 1782187447864524800
author Taveira-DaSilva, Angelo M
Steagall, Wendy K
Moss, Joel
author_facet Taveira-DaSilva, Angelo M
Steagall, Wendy K
Moss, Joel
author_sort Taveira-DaSilva, Angelo M
collection PubMed
description Lymphangioleiomyomatosis (LAM), a multisystem disease affecting predominantly premenopausal and middle-aged women, causes progressive respiratory failure due to cystic lung destruction and is associated with lymphatic and kidney tumors. In the past, the treatment of LAM comprised exclusively anti-estrogen and related hormonal therapies. These treatments, however, have not been proven effective. In this article, we discuss new findings regarding the molecular mechanisms involved in the regulation of LAM cell growth, which may offer opportunities to develop effective and targeted therapeutic agents.
format Text
id pubmed-2948329
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Medicine Reports
record_format MEDLINE/PubMed
spelling pubmed-29483292010-10-14 Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going Taveira-DaSilva, Angelo M Steagall, Wendy K Moss, Joel F1000 Med Rep Review Article Lymphangioleiomyomatosis (LAM), a multisystem disease affecting predominantly premenopausal and middle-aged women, causes progressive respiratory failure due to cystic lung destruction and is associated with lymphatic and kidney tumors. In the past, the treatment of LAM comprised exclusively anti-estrogen and related hormonal therapies. These treatments, however, have not been proven effective. In this article, we discuss new findings regarding the molecular mechanisms involved in the regulation of LAM cell growth, which may offer opportunities to develop effective and targeted therapeutic agents. Medicine Reports 2009-12-09 /pmc/articles/PMC2948329/ /pubmed/20948684 http://dx.doi.org/10.3410/M1-93 Text en © 2009 Medicine Reports Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes
spellingShingle Review Article
Taveira-DaSilva, Angelo M
Steagall, Wendy K
Moss, Joel
Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going
title Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going
title_full Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going
title_fullStr Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going
title_full_unstemmed Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going
title_short Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going
title_sort therapeutic options for lymphangioleiomyomatosis (lam): where we are and where we are going
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948329/
https://www.ncbi.nlm.nih.gov/pubmed/20948684
http://dx.doi.org/10.3410/M1-93
work_keys_str_mv AT taveiradasilvaangelom therapeuticoptionsforlymphangioleiomyomatosislamwhereweareandwherewearegoing
AT steagallwendyk therapeuticoptionsforlymphangioleiomyomatosislamwhereweareandwherewearegoing
AT mossjoel therapeuticoptionsforlymphangioleiomyomatosislamwhereweareandwherewearegoing

Ejemplares similares